Celgene Corporation

One of the March 2020 wave of D.N.J. suits asserting the '939 patent; the defendant is not confirmed in the narrative.

Celgene sued Dr. Reddy's in an ANDA/Hatch-Waxman action concerning pomalidomide (POMALYST®) patents, including U.S. Pat. Nos. 8,198,262; 8,735,428; 8,828,427; and 9,993,467. The narrative states that US3845770 does not appear to have been asserted in this case, despite its association with the patent-page litigation listing. Final judgment was entered on February 23, 2022.

Celgene sued Dr. Reddy's in D.N.J.; the '939 patent was added to the action after issuance, and the case was consolidated with 2:21-cv-02111. Terminated Apr. 6, 2022 per drugpatentwatch.

Celgene filed this D.N.J. action against Synthon (Alvogen) on the '262, '939, '428, '427 and the '647/'648/'649 patents. The docket shows termination on May 13, 2019, indicating dismissal or consolidation.

Hatch-Waxman ANDA infringement action filed by Celgene against Hetero entities; the complaint expressly asserts the '647, '648, and '649 patents. Consolidated with related 2019 cases before Judge Esther Salas / M.J. Michael A. Hammer and docket shows termination Oct. 28, 2020.

Hatch-Waxman ANDA infringement action by Celgene against Aurobindo; consolidated with the 2019 wave and later resolved by a Celgene-Aurobindo settlement in spring 2021.

Hatch-Waxman ANDA action filed by Celgene; defendants not verified (narrative notes likely Breckenridge and/or Natco but not confirmed). Consolidated with the 2019 wave.

Hatch-Waxman ANDA infringement action by Celgene against Apotex; consolidated with the 2019 wave before Judge Esther Salas / M.J. Michael A. Hammer.

Celgene sued Breckenridge (with Natco) in D.N.J. asserting the '647, '648, and '649 patents against a Pomalyst ANDA. The case was resolved via consolidation/settlement; Natco/Breckenridge later settled with agreed generic entry in Q1 2026.

Celgene filed a § 271 patent infringement action against Synthon in M.D.N.C. asserting US 8,198,262, 8,673,939, 8,735,428, and 8,828,427. The case was terminated July 25, 2018 by a stipulation of dismissal, described as a parallel/companion filing to the New Jersey action.

Celgene patent infringement action in D.N.J.; the narrative states the '262 patent is listed among the patents in this action. Sources conflict on the lead defendant/caption (Hetero vs. Dr. Reddy's), and parties reportedly include Hetero, Aurobindo, and Mylan entities.

Celgene filed a 35 U.S.C. §271 action against Par Pharmaceutical and others in D.N.J. involving the '428 patent. The case was terminated on Feb. 6, 2019, consistent with the Pomalyst ANDA settlements, though the disposition was not confirmed in the retrieved sources.

Lead consolidated case for Celgene's pomalidomide ANDA litigation against Hetero; many earlier generic ANDA cases were consolidated into this case.

Celgene's 2018 ANDA infringement case against an unidentified generic pomalidomide filer; consolidated into lead case 17-cv-3387 by Consolidation Order on 2019-01-31.

Celgene's ANDA infringement suit against Apotex; docket shows civil case terminated on 2019-02-08 upon consolidation into lead case 17-cv-3387.

Celgene's 2025 pomalidomide ANDA infringement suit against USV Private Limited; listed as remaining open.

Federal Circuit appeal of the 2:19-cv-05802 venue dismissal; affirmed on Nov. 5, 2021, holding Mylan lacked a regular and established place of business in New Jersey and that the ANDA submission, not the paragraph IV notice letter, is the operative infringing act.

Celgene brought a §271(e)(2) ANDA action against Hetero in D.N.J. regarding the '428 patent. Hetero counterclaimed for declaratory judgment of invalidity/non-infringement of the '428 patent; the court issued a Markman ruling on 'treating multiple myeloma' in the '262, '3,939 and '428 patents, and the case was resolved by settlement.

Later-filed Hetero action in D.N.J. relating to the '428 patent; the narrative states it was resolved/settled.

Hatch-Waxman ANDA action by Celgene against Teva; consolidated with the 2:19-cv-05797/05799/05802 group; later resolved by a Celgene-Teva settlement in March 2021.

Appeal captioned Celgene Corporation v. Mylan Pharmaceuticals Inc.; related to the D.N.J. Mylan venue dismissal and the consolidated 2019 action.

This Dr. Reddy's action was consolidated into 2:19-cv-15343; it is part of the Pomalyst formulation litigation involving the '939 patent.